nach oben

Diabetologia

Erschienen in:

01.02.2007 | Article

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice

verfasst von: F. Y. Chow, D. J. Nikolic-Paterson, F. Y. Ma, E. Ozols, B. J. Rollins, G. H. Tesch

Erschienen in: Diabetologia | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Tissue macrophage accumulation is thought to induce insulin resistance during obesity and stimulate the progression of diabetic nephropathy. Monocyte chemoattractant protein-1 (MCP-1) is a potent stimulator of macrophage recruitment. It is increased in adipose tissue during obesity and in diabetic kidneys, suggesting that inflammation of these tissues may be MCP-1-dependent. Based on these findings, the aim of this study was to examine whether a deficiency in MCP-1 would alter the development of type 2 diabetes and its renal complications.

Materials and methods

The role of MCP-1 in the progression of type 2 diabetes and its associated renal injury was assessed in obese db/db mice that were deficient in the gene encoding MCP-1 (Ccl2).

Results

The incidence and development of type 2 diabetes were similar in Ccl2 ^+/+ and Ccl2 ^−/− db/db mice between 8 and 32 weeks of age. Body mass, hyperglycaemia, hyperinsulinaemia, glucose and insulin tolerance, plasma triacylglycerol and serum NEFA were not different between these strains. Pathological changes in epididymal adipose tissue, including increases in macrophage accumulation and Tnfa mRNA and reductions in Adipoq mRNA, were unaffected by the absence of MCP-1. In contrast, kidney macrophage accumulation and the progression of diabetic renal injury (albuminuria, histopathology, renal fibrosis) were substantially reduced in Ccl2 ^−/− compared with Ccl2 ^+/+ db/db mice with equivalent diabetes.

Conclusions/interpretation

Our study demonstrates that MCP-1 promotes type 2 diabetic renal injury but does not influence the development of obesity, insulin resistance or type 2 diabetes in db/db mice. MCP-1 plays a critical role in inflammation of the kidney, but not adipose tissue, during the progression of type 2 diabetes.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMedCrossRef

Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMedCrossRef

Furuta T, Saito T, Ootaka T et al (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480–485PubMed

Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65:116–128PubMedCrossRef

Weisberg SP, Hunter D, Huber R et al (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115–124PubMedCrossRef

Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A (1993) Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268:26055–26058PubMed

Stephens JM, Lee JL, Pilch PF (1997) Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and glut4 expression without loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976PubMedCrossRef

Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138–1143PubMedCrossRef

Arkan MC, Hevener AL, Greten FR et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191–198PubMedCrossRef

10.

Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 19:2987–2996PubMedCrossRef

11.

Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH (2005) ICAM-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16:1711–1722PubMedCrossRef

12.

Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR (1999) MCP-1 dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Faslpr mice. J Exp Med 190:1813–1824PubMedCrossRef

13.

Biswas SK, Sodhi A, Paul S (2001) Regulation of nitric oxide production by murine peritoneal macrophages treated in vitro with chemokine monocyte chemoattractant protein 1. Nitric Oxide 5:566–579PubMedCrossRef

14.

Biswas SK, Sodhi A (2002) In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1: upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway. J Interferon Cytokine Res 22:527–538PubMedCrossRef

15.

Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein-1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100:7265–7270PubMedCrossRef

16.

Takahashi K, Mizuarai S, Araki H et al (2003) Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278:46654–46660PubMedCrossRef

17.

Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD (2001) Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 175:81–92PubMedCrossRef

18.

Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690PubMedCrossRef

19.

Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26:2421–2425PubMedCrossRef

20.

Morii T, Fujita H, Narita T et al (2003) Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 17:11–15PubMedCrossRef

21.

Lu B, Rutledge BJ, Gu L et al (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187:601–608PubMedCrossRef

22.

Kumar S, McCue P, Dunn SR (2003) Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284:F1138–F1144

23.

van den Berg TK, van Die I, de Lavalette CR et al (1996) Regulation of sialoadhesin expression on rat macrophages. Induction by glucocorticoids and enhancement by IFN-beta, IFN-gamma, IL-4 and lipopolysaccharide. J Immunol 157:3130–3138PubMed

24.

Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH (2006) Monocyte chemoattractant protein-1 promotes diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73–80PubMedCrossRef

25.

Masaki T, Chow F, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2003) Heterogeneity of antigen expression explains controversy over glomerular macrophage accumulation in mouse glomerulonephritis. Nephrol Dial Transplant 18:178–181PubMedCrossRef

26.

Di Gregorio GB, Yao-Borengasser A, Rasouli N et al (2005) Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance and reduction by pioglitazone. Diabetes 54:2305–2313PubMedCrossRef

27.

Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494–1505PubMedCrossRef

28.

Kamei N, Tobe K, Suzuki R et al (2006) Overexpression of MCP-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem DOI 10.1074/jbc.M601284200

29.

Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280:12888–12895PubMed

30.

Chen A, Mumick S, Zhang C et al (2005) Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13:1311–1320PubMed

31.

Skurk T, Herder C, Kraft I, Muller-Scholze S, Haumer H, Kolb H (2005) Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology 146:1006–1011PubMedCrossRef

32.

Levine JA, Jensen MD, Eberhardt NL, O’Brien T (1998) Adipocyte macrophage-colony stimulating factor is a mediator of adipose tissue growth. J Clin Invest 101:1557–1564PubMedCrossRef

33.

Le Meur Y, Tesch GH, Hill PA et al (2002) Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leuk Biol 72:530–537

Titel: Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice
verfasst von: F. Y. Chow
D. J. Nikolic-Paterson
F. Y. Ma
E. Ozols
B. J. Rollins
G. H. Tesch
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 2/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0497-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects

Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects

Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia

PTEN targeting: the search for novel insulin sensitisers provides new insight into obesity research

Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin